Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Ann Hepatol ; 17(4): 585-591, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29893699

RESUMEN

INTRODUCTION AND AIM: The prevalence of obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease are increasing. Type 2 diabetes mellitus may aggravate non-alcoholic fatty liver disease, increasing the risk of developing cirrhosis and hepatocellular carcinoma. This study aims to determine the effect of type 2 diabetes mellitus and insulin therapy on non-alcoholic fatty liver disease in the patients with morbid obesity. MATERIAL AND METHODS: Clinical, anthropometric and laboratory data were analyzed together with intraoperative liver biopsies from morbidly obese patients undergoing bariatric surgery. RESULTS: 219 patients with morbid obesity were evaluated. Systemic arterial hypertension (55.9% vs. 33.8%, p = 0.004) and dyslipidemia (67.1% vs. 39.0%, p < 0.001) were more prevalent in patients with diabetes when compared to patients without diabetes. In multivariate analysis, type 2 diabetes mellitus was an independent risk factor for severe steatosis (RR = 2.04, p = 0.023) and severe fibrosis (RR = 4.57, p = 0.013). Insulin therapy was significantly associated with non-alcoholic steatohepatitis (RR = 1.89, p = 0.001) and fibrosis (RR = 1.75, p = 0.050) when all patients were analysed, but when only patients with diabetes were analysed, insulin therapy was not associated with non-alcoholic steatohepatitis or fibrosis. CONCLUSION: Type 2 diabetes mellitus plays an important role in the progression of non-alcoholic fatty liver disease as an independent risk factor for severe fibrosis.


Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Enfermedad del Hígado Graso no Alcohólico/epidemiología , Obesidad Mórbida/epidemiología , Adulto , Brasil/epidemiología , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/epidemiología , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad del Hígado Graso no Alcohólico/diagnóstico , Obesidad Mórbida/diagnóstico , Prevalencia , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad
2.
Surg Laparosc Endosc Percutan Tech ; 25(4): 317-20, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26018054

RESUMEN

BACKGROUND: Laparoscopic cholecystectomy is the gold standard for gallstone disease. Postoperative pain still is considerable and may prevent early discharge. METHODS: A randomized controlled blind clinical trial was designed for all patients undergoing laparoscopic cholecystectomy. The groups were control (group A), preincisional trocar wound infiltration with bupivacaine (group B), and preincisional trocar wound infiltration and intraperitoneal instillation of bupivacaine over the gallbladder and liver surface before starting the dissection (group C). The operative technique and postoperative analgesia were standardized. The pain in 6 hours was assessed with the visual analog scale as the primary outcome. RESULTS: The visual analog pain scores in the intraperitoneal bupivacaine were similar to the trocar wound infiltration alone and both were lower than the control group (P=0.05616). CONCLUSIONS: Intraperitoneal application of local anesthetics and trocar wound infiltration did not lower the pain scores in comparison with trocar wound infiltration in our study.


Asunto(s)
Anestesia Local/métodos , Bupivacaína/administración & dosificación , Colecistectomía Laparoscópica/métodos , Colelitiasis/cirugía , Dolor Postoperatorio/prevención & control , Anestésicos Locales/administración & dosificación , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Dolor Postoperatorio/diagnóstico , Estudios Retrospectivos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA